Replimune Group
Latest round
- Series B
Last raised
- Sep 2017
Total raised
- $85M
Investors
- 8
About Replimune Group
Replimune Group, Inc.Founded in 2015 and headquartered in Woburn, US, Replimune specializes in oncolytic immunotherapy for cancer treatment.00 mn.Replimune specializes in developing innovative oncolytic immunotherapies aimed at addressing the complexities of cancer treatment. Their core product offerings include RP1 and RP2, designed to locally target tumors while simultaneously modulating the tumor microenvironment to elicit robust systemic immune responses. These therapies are being tested across various clinical trials addressing a range of solid tumor cancers, including melanoma, liver cancer, and non-melanoma skin cancers. Intended primarily for patients with difficult-to-treat malignancies, Replimune's therapies are undergoing evaluations both as standalone treatments and in combination with established immunotherapeutic agents like Nivolumab.Replimune generates revenue through strategic partnerships and collaborations within the biopharmaceutical sector, focusing on clinical trial agreements and potential future licensing arrangements. Revenue transactions are structured around milestones associated with the development and commercialization of their investigational therapies. These agreements often involve payments contingent upon the achievement of specific clinical endpoints or regulatory approvals. While specific pricing details for their therapies have not been disclosed, the business model suggests a reliance on partnerships with healthcare systems and research institutions looking to incorporate advancements in cancer treatments into their offerings. The company will focus on launching their innovative therapies while expanding into new markets, specifically targeting additional regions in Europe and North America by 2024. Continued commitment to clinical trials will drive the advancement of their products, aligning with their objective to establish a stronger foothold in the biopharmaceutical landscape.
Who invested in Replimune Group
8 investors across 2 rounds
See all investors in Replimune Group
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Replimune Group
Who invested in Replimune Group?
Replimune Group has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Replimune Group raised?
Replimune Group has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Replimune Group last raise money?
Replimune Group's most recent round on record is a Series B, in Sep 2017.
What does Replimune Group do?
Replimune Group is a biotechnology company.
Where is Replimune Group headquartered?
Replimune Group is headquartered in Woburn, US.
Which VCs invest in companies like Replimune Group?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Replimune Group's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Replimune Group? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.